搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
centerforbiosimilars
1 小时
BioRationality—The Evolution of the BPCIA and the Bright Future of Biosimilars in the US
The Biologics Price Competition and Innovation Act (BPCIA) of 2010 initially posed significant barriers to biosimilar ...
centerforbiosimilars
1 天
Biosimilars Policy Roundup for September 2024—Podcast Edition
On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which ...
centerforbiosimilars
7 天
Fourth Ustekinumab Biosimilar, Otulfi, Approved in US
Otulfi was approved simultaneously in the European Union. In the US, it will launch in February 2025.
centerforbiosimilars
3 天
Eye on Pharma: High-Strength Trastuzumab Biosimilar; Originator Coverage Removals; CHMP ...
The FDA approved a new strength of a trastuzumab biosimilar; UnitedHealth will remove reference adalimumab from some ...
centerforbiosimilars
8 天
Future Biosimilar Trends, Challenges, and Opportunities
Ivo Abraham, PhD, RN, University of Arizona Cancer Center, explains how biosimilars are becoming more accessible but face ...
centerforbiosimilars
2 天
Treatment Persistence, Safety After Switching to Infliximab Biosimilars in Canadians With IBD
A retrospective study of a mandatory nonmedical switch in Canada found no significant differences in rates of treatment persistence, loss of response, or adverse events in patients with inflammatory ...
centerforbiosimilars
6 天
Biosimilar Policy Roundup—September 2024
In September 2024, the FDA approved a new biosimilar for treating retinal conditions, marking a significant development in ...
centerforbiosimilars
13 天
AAM Report: Despite Massive Savings, Patient OOP Costs on Biosimilars, Generics Remain High ...
Part 2 of our series diving into the Association for Accessible Medicines' (AAM) latest report discusses that while generics ...
centerforbiosimilars
13 天
BioRationality—The Missing Rationality in Biosimilar Discussions and the Path Forward
The article by Sarfaraz K. Niazi, PhD, critiques the irrationality surrounding biosimilars, suggesting that regulatory ...
centerforbiosimilars
11 天
Eye on Pharma: EC Approved Ustekinumab; Zymfentra Expansion; Biosimilar Policy Briefing
The European Commission (EC) approved Celltrion's ustekinumab biosimilar for chronic inflammatory diseases, Celltrion ...
centerforbiosimilars
6 天
Patient-Reported Outcomes Similar Between Adalimumab-adbm, Reference Product in VOLTAIRE-RA ...
A summary of research written by Vibeke Strand, MD, clinical professor in division of immunology/rheumatology at Stanford ...
centerforbiosimilars
10 天
The Top 5 Biosimilar Articles for the Week of September 23
Number 1: Amgen’s Pavblu (aflibercept-ayyh) is the fifth biosimilar referencing Eylea (aflibercept) to be approved for ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈